Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | STAT6 | P42226 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1237955 | 0.97 | LMNA (0.41) | LMNASLC22A2SLC22A1GRIN2DGRIN3B | |
| Sulfuric Acid SCHEMBL15211001 | 0.85 | KCNH2 (0.36) | — | |
| SCHEMBL27982220 | 0.85 | — | — | |
| SCHEMBL27309162 | 0.73 | LMNA (0.42) | LMNASLC22A2SLC22A1GRIN2DGRIN3B | |
| SCHEMBL1397352 | 0.73 | MAPT (0.33) | — | |
| SCHEMBL19355051 | 0.71 | — | — | |
| Water SCHEMBL6938407 | 0.71 | HSD11B1 (0.32) | — | |
| SCHEMBL13718444 | 0.71 | — | — | |
| SCHEMBL2264953 | 0.69 | PKM (0.39) | LMNASLC22A2SLC22A1GRIN2DGRIN3B | |
| SCHEMBL6526108 | 0.69 | GRIN2D (0.40) | LMNASLC22A2SLC22A1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9301950-B2 | Adamantane analogs | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-04-05 | — | — | US | claimed |
| EP-2817003-A1 | COMPOUNDS FOR TREATING PARVOVIRUS INFECTION | Aratana Therapeutics NV (BE) | 2014-12-31 | — | — | EP | claimed |
| CN-104220052-A | Compounds for treating parvovirus infection | OKAPI SCIENCES NV | 2014-12-17 | — | — | CN | claimed |
| WO-2013124403-A1 | COMPOUNDS FOR TREATING PARVOVIRUS INFECTION | OKAPI SCIENCES NV (BE) | 2013-08-29 | — | — | WO | claimed |
| US-20120270917-A1 | ADAMANTANE ANALOGS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-10-25 | — | — | US | claimed |
| WO-2011022191-A1 | ADAMANTANE ANALOGS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-02-24 | — | — | WO | claimed |
| EP-0647629-B1 | Neurotensin active substituted 1-naphthylpyrazole-3-carboxamides, their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1999-07-07 | — | — | EP | claimed |
| US-9840465-B2 | Antiviral compounds | UNIV BRIGHAM YOUNG (US) | 2017-12-12 | — | — | US | disclosed |
| US-9726976-B2 | Photoresist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9726976-B2 | Photoresist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9726976-B2 | Photoresist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-9301950-B2 | Adamantane analogs | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301950-B2 | Adamantane analogs | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-04-05 | — | — | US | disclosed |
| US-20110065041-A1 | PHOTORESIST COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-17 | — | — | US | disclosed |
| WO-2011022191-A1 | ADAMANTANE ANALOGS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011022191-A1 | ADAMANTANE ANALOGS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-02-24 | — | — | WO | disclosed |
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-09-25 | — | — | US | disclosed |
| CN-101238107-A | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACEUTICALS SA (CH) | 2008-08-06 | — | — | CN | disclosed |
| EP-1902034-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | Glenmark Pharmaceuticals S.A. (CH) | 2008-03-26 | — | — | EP | disclosed |
| WO-2006129178-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270917-A1 | ADAMANTANE ANALOGS | HAVCR2, ADORA2A, ADORA1 | LMNA 2893/4885SLC22A2 1112/4885SLC22A1 993/4885 |
| US-20080234259-A1 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation | CNR2, CNR1, OPRL1 | LMNA 2774/4885SLC22A2 4061/4885SLC22A1 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.